Examples of Medication-Assisted Treatment Programs for Opioid Use Disorder

Recent Trends in Medication-Assisted Treatment

Over the past several years, medication-assisted treatment (MAT) has moved from a niche intervention to a widely endorsed standard of care for opioid use disorder. Federal and state agencies have expanded access through telemedicine waivers, mobile treatment units, and streamlined prescribing for buprenorphine. Programs now commonly combine FDA-approved medications—methadone, buprenorphine, or naltrexone—with counseling and behavioral therapies. The shift toward patient-centered, low-barrier access reflects a growing recognition that retention in treatment reduces overdose risk and improves long-term outcomes.

Background: Core Program Models

The three medication options form the backbone of most MAT programs. Each is delivered through distinct settings:

• Opioid treatment programs (OTPs) — Federally regulated clinics that dispense methadone daily under direct observation, often also offering buprenorphine. These are the longest-established model, requiring in-person visits initially.
• Office-based opioid treatment (OBOT) — Licensed physicians, nurse practitioners, or physician assistants prescribe buprenorphine (or injectable naltrexone) from their private practices or community health centers, with less restrictive visit schedules than OTPs.
• Hub-and-spoke networks — Specialized addiction medicine hubs manage complex cases and stabilize patients, while spoke providers (primary care, rural clinics) deliver ongoing maintenance therapy. This model emerged in states like Vermont to extend reach.
• Tele-MAT programs — Remote prescribing and monitoring via video visits, originally expanded during the public health emergency and now increasingly permanent in many jurisdictions.

User Concerns: Access, Stigma, and Practical Barriers

Individuals seeking MAT often report several recurring concerns:

• Geographic availability — Rural areas may lack OTPs or buprenorphine prescribers, forcing long travel distances or reliance on telemedicine, which requires internet access.
• Cost and insurance coverage — Not all plans cover all formulations; prior authorization requirements and out-of-pocket costs can disrupt continuity.
• Stigma and program rules — Strict attendance policies, frequent drug testing, and negative interactions with staff discourage some patients from staying engaged.
• Withdrawal and induction hurdles — Starting buprenorphine requires careful timing to avoid precipitated withdrawal, and some patients find the process intimidating without adequate support.
• Fear of long-term dependency — Some individuals or their families worry that maintenance medications merely replace one addiction, despite evidence showing improved survival and functioning.

Likely Impact of Current Program Expansions

The ongoing expansion of MAT programs is expected to affect public health outcomes in measurable ways:

• Reduced overdose mortality — Broader access, especially to buprenorphine and injectable naltrexone, correlates with lower community-level overdose rates in studies comparing program-rich versus program-poor areas.
• Improved treatment retention — Low-barrier programs (same-day induction, flexible dosing, telemedicine) consistently show higher six-month retention than traditional rigid models.
• Shift toward office-based and tele-MAT — This reduces the stigma of attending OTPs and allows patients to integrate treatment with primary care, but it also raises concerns about monitoring for diversion and co-use of other substances.
• Greater emphasis on psychosocial support — Even with medications, many programs are now embedding peer recovery coaches, case management, and mental health treatment to address underlying trauma and co-occurring conditions.

What to Watch Next

Several developments could shape how MAT programs evolve in the near term:

• Reauthorization of telemedicine flexibilities — Federal decisions on permanent remote prescribing rules will affect many rural and mobility-limited patients.
• Expansion of mobile methadone units — Early pilot programs in areas like New York City and West Virginia are being evaluated; results could spur regulatory changes.
• Integration of MAT into emergency departments and jails — Initiation of buprenorphine in these settings has shown promise and is being adopted by more states.
• Emergence of long-acting injectable and implant formulations — These may reduce daily compliance burdens, particularly for patients who struggle with oral medications or stigma.
• Data on patient preferences — As programs move toward more individualized care, researchers are tracking which models best serve specific populations—people with chronic pain, pregnant women, adolescents, and those with co-occurring stimulant use.